Torrent Pharmaceuticals declared their Q2 FY24 results on 23 Oct, 2023. The topline increased by 16.11% & the profit increased by 23.72% YoY. As compared to the previous quarter the revenue grew by 2.66% and the profit increased by 2.12%.
The Selling, general & administrative expenses rose by 0.8% q-o-q & increased by 27.66% Y-o-Y.
The operating income was up by 4% q-o-q & increased by 20.93% Y-o-Y.
The EPS is ₹11.39 for Q2 FY24 which increased by 23.54% Y-o-Y.
Torrent Pharmaceuticals has delivered -1.83% return in the last 1 week, 15.78% return in last 6 months and 21.07% YTD return.
Currently the Torrent Pharmaceuticals has a market cap of ₹63536.36 Cr and 52wk high/low of ₹2094.55 & ₹1445.55 respectively.
As of 25 Oct, 2023 out of 28 analysts covering the company, 3 analysts have given Sell rating, 6 analysts have given Hold rating, 9 analysts have given Buy rating &10 analysts have given Strong Buy rating.
The consensus recommendation as on 25 Oct, 2023 was to Buy.
| Period | Q2 FY24 | Q1 FY24 | Q-o-Q Growth | Q2 FY23 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 2660 | 2591 | +2.66% | 2291 | +16.11% |
| Selling/ General/ Admin Expenses Total | 503 | 499 | +0.8% | 394 | +27.66% |
| Depreciation/ Amortization | 201 | 191 | +5.24% | 163 | +23.31% |
| Total Operating Expense | 2036 | 1991 | +2.26% | 1775 | +14.7% |
| Operating Income | 624 | 600 | +4% | 516 | +20.93% |
| Net Income Before Taxes | 559 | 531 | +5.27% | 463 | +20.73% |
| Net Income | 386 | 378 | +2.12% | 312 | +23.72% |
| Diluted Normalized EPS | 11.39 | 11.18 | +1.88% | 9.22 | +23.54% |
FAQs
Question : What is the Q2 FY24 profit/Loss as per company?
Ans : ₹386Cr
Question : What is Q2 FY24 revenue?
Ans : ₹2660Cr
“Exciting news! Mint is now on WhatsApp Channels 🚀 Subscribe today by clicking the link and stay updated with the latest financial insights!” Click here!
Download The Mint News App to get Daily Market Updates & Live Business News.
Updated: 25 Oct 2023, 02:53 AM IST